Orilanolimab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameOrilanolimab

Drug Alias NameSYNT-001ALXN-1830SYNT1001

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionIgG receptor FcRn large subunit p51 antagonists

TargetsIgG receptor FcRn large subunit p51

Therapy Area/IndicationsPemphigusAnemia, Hemolytic, AutoimmuneMyasthenia Gravis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesNew ZealandUnited Kingdom +[4]

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesSyntimmune Inc

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsPemphigusAnemia, Hemolytic, AutoimmuneMyasthenia Gravis

ATC CodeN/A